FirstIgnite is supporting MaineHealth’s antibody therapy for triple-negative breast cancer (TNBC). This technology utilizes humanized anti-programmed cell death protein 1 (anti-PD-1) antibodies to treat TNBC by targeting patient-derived xenograft (PDX) tumor models in humanized mice. Through this research, the use of TNBC PDXs in humanized mice has been demonstrated as an effective approach for exploring the potential of immune-based therapies in cancer treatment.
This technology has the potential to advance the development of new immunotherapies for TNBC and other types of cancer, improving preclinical testing of immune-based therapies for cancer treatment, and could lead to the development of personalized medicine and targeted cancer treatments. The global market for breast cancer therapeutics was valued at $21.58 billion in 2019 and is expected to grow to $55.27 billion by 2027.
The MaineHealth team is seeking companies who have new CPIs (Checkpoint Inhibitors) in development or advance in their development to be tested in the TNBC model at MaineHealth. Is your company the right fit? If you’d be available for a conversation with the MaineHealth team, you can schedule a time directly on their team’s calendar here.
